Axogen, Inc.

Axogen develops and commercializes regenerative medicine technologies designed to repair and regenerate peripheral nerves. Its product portfolio features processed human nerve allografts, including Avance, as well as extracellular matrix devices such as Axoguard nerve connectors, protectors, and caps. It also offers Avive+ soft tissue matrix for surgical wound healing. The company organizes its business across four primary clinical application areas: extremities, oral maxillofacial and head and neck, breast reconstruction neurotization, and urology. Its solutions are utilized by surgeons and healthcare providers treating patients with traumatic nerve damage or surgical nerve transections.

The company supplies products in the United States, Canada, Germany, the United Kingdom, Spain, and several other international countries, with the domestic market accounting for most distribution. Operational facilities include a 107,000-square-foot biologic processing and packaging center on 8.5 acres in Vandalia, Ohio, alongside partner facilities in Dayton, Ohio, and West Lafayette, Indiana. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Axogen's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 622 employees, substantially all of whom were full-time.”